

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number  
**WO 03/099785 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 207/34**

**Ramanbhai [IN/IN]; Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN).**

(21) International Application Number: **PCT/IN02/00220**

(22) International Filing Date:  
15 November 2002 (15.11.2002)

(74) Agents: **SUBRAMANIAM, Hariharan** et al.; Subramaniam, Nataraj and Associates, E-556, Greater Kailash II, New Delhi 110 048 (IN).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
472/MUM/2002 28 May 2002 (28.05.2002) IN

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **CADILA HEALTHCARE LIMITED [IN/IN];** Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN).

(84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NH, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AGARWAL, Virendra, Kumar [IN/IN];** Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN). **VAKIL, Manish, Harshadbhai [IN/IN];** Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN). **PANDITA, Kanwal [IN/IN];** Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN). **MANAKIWALA, Satish, Champaklal [IN/IN];** Zydus Tower, Satellite Cross Road, Ahmedabad 380 015, Gujarat (IN). **PATEL, Pankaj,**

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/099785 A1

(54) Title: **PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM**

(57) Abstract: The present invention relates to a process for the preparation of amorphous atorvastatin calcium. In essence, the process comprises dissolving form - I or a mixture of crystalline and amorphous atorvastatin calcium in a solvent consisting of an aliphatic acyclic ketone, filtering the solution and removing the solvent at 40 to 50 °C under vacuum.

## PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM


### Field of invention

The present invention relates to a process for the production of amorphous atorvastatin calcium.

### Background of the invention

Atorvastatin, the substance known by the chemical name [R-(R\*,R\*)]-2-(4-FLUOROPHENYL)- $\beta$ , $\delta$ -DIHYDROXY-5-(1-METHYLETHYL) PHENYL-4-[(PHENYLAMINO) CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID is a member of the class of drugs called statins. Statin drugs are currently the most therapeutically effective drugs available for the treatment of hyperlipidemia and hypercholesterolemia, both of which are risk factors for arteriosclerosis and coronary heart disease. Open dihydroxy carboxylic acid, lactone and various salt forms of atorvastatin have been synthesized.

According to the disclosure contained in the U.S. Patent No. 5273995, R-form of the ring opened acid form has surprising inhibition of the biosynthesis of cholesterol. Atorvastatin in its calcium salt form, i.e. [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) having formula 1 is more suited for formulations and has been recommended as a drug.



20

United states patents 5,003,080; 5,097,045; 5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174; 5,245,047; 5,248,793; 5,273,995; 5,280,126; 5,298,627; 5,342,952; 5,385,929; 5,397,792; European Patent 409,281; and PCT publication No. 8,907,598 describe various processes and key intermediates for preparing atorvastatin.

Atorvastatin is preferably prepared as its calcium salt, i.e. [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2 : 1) since the calcium salt is desirable and it enables easy formulation of atorvastatin for example, tablets, capsules, lozenges, powder and the like for oral administration. Different polymorphic forms of atorvastatin calcium such as Form I, Form II, Form III, Form IV, Form V and amorphous form have been reported in WO 97/03958, WO 97/03959, WO 97/03960 and WO 01/36384.

It is known that the amorphous forms in a number of pharmaceutical substances exhibit different dissolution characteristics and bioavailability patterns compared to crystalline forms (Knno T. Chem. Pharm. Bull. 1990, 38, 2003-2007). In some therapeutical indications the bioavailability is one of the key parameters determining the form of the substance to be used in a pharmaceutical formulation. Since process for the crystallization and the preparation, respectively of the amorphous substance are sometimes difficult to be performed and as a result the product obtained is in a mixture of amorphous and crystalline form. There is a constant need for processes which enable the preparation of atorvastatin in an amorphous form without simultaneous formation of crystalline forms or which will enable the conversion of crystalline forms into the amorphous form.

Atorvastatin calcium is very slightly soluble in water and it has been found that the crystalline form is less readily soluble than the amorphous form, which may cause problems in the bioavailability of atorvastatin. It has been found that the production of amorphous atorvastatin accordingly to the previously disclosed processes was not consistently reproducible. Therefore various processes have been developed for converting the crystalline form in to amorphous form.

WO 97/03960 describes a procedure for converting the crystalline form of atorvastatin calcium to the amorphous form. Process disclosed therein comprises dissolving crystalline form I atorvastatin in a non-hydroxylic solvent like tetrahydrofuran or mixture of tetrahydrofuran and toluene. The process involves complete removal of the solvent under high temperature (about 90°C) and under high vacuum (about 5 mm) for 3-5 days. Exposure of the material to high temperature for several days may lead to degradation of the product. This makes the process very inconvenient to operate on a large scale. Slow removal of solvent at a manufacturing scale renders this process as less productive.

The process for the preparation of amorphous atorvastatin described in WO 00/71116 involves dissolving crystalline form in tetrahydrofuran and reprecipitating amorphous atorvastatin by adding cyclohexane or n-hexane n-heptane.

WO 01/28999 describes the purification of crude amorphous atorvastatin calcium by dissolving crude amorphous material in large excess of boiling ethanol or 2-propanol and filtering the hot solution and recovering the material at low temperature.

WO 01/42209 describes the preparation of amorphous atorvastatin calcium from  
5 form I by dissolving crystalline form in about 20 – 25 times of methanol, ethanol or acetone, concentrating the solution by distillation and precipitating the product by adding diethylether. The process disclosed therein also is not recommended for commercial production of amorphous atorvastatin calcium due to the use of large excess of diethylether, which may not be safe on plant level.

#### 10 **Summary of the invention**

It is the object of the invention to eliminate the drawbacks of the known procedures and to provide a simple reproducible and economically feasible process for the preparation of high purity and uniformly amorphous atorvastatin calcium.

The procedures to manufacture amorphous atorvastatin calcium disclosed in prior  
15 arts employ a large excess of solvent or a mixture of solvents, and removing the solvents at high temperature for a longer period of time. Laboratory trials conducted based on all prior arts give amorphous atorvastatin calcium accompanied with higher level of residual solvents i.e. 10,000 to 20,000 ppm, the level of residual solvents is not reduced even at higher temperature under vacuum. The prolonged heating to reduce the level of residual solvents  
20 did not result in decrease of the level of residual solvents, instead an appreciable degradation of the product was observed.

The above object is achieved by process of the invention, which employs a single solvent of aliphatic acyclic ketone group, and the level of residual solvent in final product is less than 5000 ppm which is easily achieved by drying the product at relatively less  
25 temperature i.e. 45 to 50 °C under vacuum for 10 to 15 hours. The amorphous atorvastatin calcium prepared by the process disclosed herein does not show any degradation of the product.

According to the present invention, amorphous atorvastatin calcium is produced by dissolving form - I or a mixture of crystalline and amorphous atorvastatin calcium in  
30 aliphatic acyclic ketones filtering the solution and removing the solvent at 45 to 50 °C under vacuum till desired level of residual solvent below 5000 ppm is achieved providing pure amorphous atorvastatin calcium as revealed by X-ray powder diffractogram.

Preferably, the solvent is selected from acetone, 2-butanone, 3-pentanone, 2-pentanone or 2-hexanone. Acetone is the most preferred solvent due to its lowest boiling

point i.e. 56 °C as compared to other aliphatic acyclic ketones. Employing acetone as a solvent gives desired level of residual solvent in final product at relatively low temperature i.e. 45 to 50°C under vacuum for 10 to 15 hours, while other aliphatic acyclic ketones gives higher level of residual solvents even at higher temperature under vacuum for prolonged heating.

Atorvastatin calcium form - I can easily be dissolved in 10 - 15 volumes of acetone at 45 - 50 °C while a mixture of crystalline and amorphous atorvastatin calcium requires 30 - 50 volumes of acetone depending on the composition of crystalline and amorphous atorvastatin calcium in a particular mixture.

The invention disclosed herein gives pure amorphous atorvastatin calcium by using atorvastatin calcium form - I or any mixture of crystalline and amorphous atorvastatin calcium demonstrating the wide scope and capability of the process disclosed herein.

#### **Detailed description of the invention**

According to the process of present invention form - I of atorvastatin calcium is dissolved in 15 volumes of acetone at 40 - 45 °C and the solution is filtered to remove suspended and extraneous material. The filtered solution is concentrated at 45 - 50 °C under vacuum leaving behind approximately 2.5 - 3 volumes of acetone. The concentrated solution of atorvastatin calcium in acetone is placed on glass tray, which is put in vacuum dryer. The remaining acetone is removed at 45 - 50 °C under vacuum for 2 - 3 hours resulting in the white flakes of amorphous atorvastatin calcium which is uniformly powdered. The powdered amorphous atorvastatin calcium is dried at 45 - 50 °C under vacuum for 15 hours to get acetone content in final product less than 5000 ppm. X-ray powder diffractogram reveals the material to be completely amorphous (figure - 2)

According to the present invention a mixture of crystalline and amorphous atorvastatin calcium is dissolved at 50 - 55 °C in 30 - 50 volumes of acetone depending on the composition of crystalline and amorphous atorvastatin calcium in the mixture. The solution is filtered to remove suspended particles and extraneous material. The filtered solution is concentrated at 45 - 50 °C under vacuum leaving behind approximately 2.5 - 3 volumes of acetone. The concentrated solution of atorvastatin calcium in acetone is placed on glass tray, which is put in vacuum dryer. The remaining acetone is removed at 45 - 50 °C under vacuum for 2 - 3 hours resulting in the white flakes of amorphous atorvastatin calcium, which is uniformly powdered. The powdered amorphous atorvastatin calcium is dried at 45 - 50 °C under vacuum for 15 hours to get acetone content in final product less

than 5000 ppm. X-ray powder diffractogram reveals the material to be completely amorphous (figure - 4)

The present invention will now be described with reference to the following non-limiting Examples and the accompanying drawings in which:

5        Figure 1 depicts X-ray Powder diffractogram of atorvastatin calcium form - I. The horizontal axis presents  $2\theta$  and the vertical axis corresponds to peak intensity.

Figures 2 depicts X-ray powder diffractogram of amorphous atorvastatin calcium. The horizontal axis presents  $2\theta$  and the vertical axis corresponds to peak intensity.

10       Figures 3 depicts X-ray powder diffractogram of mixture of crystalline and amorphous atorvastatin calcium. The horizontal axis presents  $2\theta$  and the vertical axis corresponds to peak intensity.

Figures 4 depicts X-ray powder diffractogram of amorphous atorvastatin calcium. The horizontal axis presents  $2\theta$  and the vertical axis corresponds to peak intensity.

**Example : 1**

15       10 g of Atorvastatin calcium form - I was dissolved in 150 ml of acetone at 40 to 45 °C. The solution was filtered and acetone was removed by vacuum distillation at 45 to 50 °C leaving behind approximately 30 ml of acetone. The concentrated solution of atorvastatin calcium in acetone was further dried in vacuum oven at 45 to 50 °C for 3 hours providing white flakes of amorphous atorvastatin calcium which was uniformly powdered. The  
20       powdered amorphous atorvastatin calcium was dried at 45 - 50 °C under vacuum for 15 hours to give 8.5 g white solid material with acetone content in final product being less than 5000 ppm. X-ray powder diffractogram revealed the material to be completely amorphous (figure - 2).

**Example 2 :**

25       10 g of a mixture of crystalline and amorphous Atorvastatin calcium was dissolved in 500 ml of acetone at 50 to 55 °C. The solution was filtered and acetone was removed by vacuum distillation at 45 to 50 °C leaving behind approximately 30 ml of acetone. The concentrated solution of atorvastatin calcium in acetone was further dried in vacuum oven at 45 to 50 °C for 3 hours providing white flakes of amorphous atorvastatin calcium which  
30       was uniformly powdered. The powdered amorphous atorvastatin calcium was dried at 45 - 50 °C under vacuum for 15 hours to give 8.5 g white solid material with acetone content in final product less than 5000 ppm. X-ray powder diffractogram reveals the material to be completely amorphous (figure - 4).

## CLAIMS

1. A process for the preparation of amorphous atorvastatin calcium which comprises dissolving form - I or a mixture of crystalline and amorphous atorvastatin calcium in  
5 a solvent consisting of an aliphatic acyclic ketone, filtering the solution and removing the solvent at 40 to 50 °C under vacuum .
2. A process as claimed in claim 1 wherein after dissolving said form - I or a mixture of crystalline and amorphous atorvastatin calcium in -said solvent, the resultant solution is filtered to remove suspended and extraneous material, subjecting  
10 resultant solution to partial concentration to leave behind approximately 2.5 - 3 volumes of solvent, further removing said solvent in vacuum dryer, grinding white flakes so produced to uniform powder and further drying said uniform powder in vacuum dryer to obtain atorvastatin calcium in amorphous form.
3. A process as claimed in claim 1 or 2 wherein said solvent is selected from acetone,  
15 2-butanone, 3-pentanone, 2-pentanone or 2-hexanone.
4. A process as claimed in claim 3 wherein the amount of said solvent is 10 - 20 volumes for atorvastatin calcium form - I and 30 - 70 volumes for a mixture of crystalline and amorphous atorvastatin calcium.
5. A process as claimed in claim 4 wherein the amount of said solvent is 15 volumes of  
20 acetone for atorvastatin calcium form - I and 50 volumes of acetone for a mixture of crystalline and amorphous atorvastatin calcium.
6. A process as claimed in any preceding claim wherein acetone is removed under vacuum at 45 - 50 °C leaving behind 2 - 5 volumes of acetone.
7. A process as claimed in claim 6 wherein acetone is removed under vacuum at 45 -  
25 50 °C leaving behind 2.5 - 3 volumes of acetone.
8. A process as claimed in claim 7 wherein acetone is further removed in vacuum dryer at 30 - 50 °C.
9. A process as claimed in claim 8 wherein acetone is further removed in vacuum dryer at 45 - 50 °C.
- 30 10. A process as claimed in any preceding claim wherein uniform powder is dried in vacuum dryer at 30 - 50 °C for 5 - 25 hours.
11. A process as claimed in claim 10 wherein uniform powder is dried in vacuum dryer at 45 - 50 °C for 10 - 15 hours.




Fig. 1







Fig. 2



April-12-2002 16:13:13 Page-1

Fig. 3




Fig. 4

## INTERNATIONAL SEARCH REPORT

Intern Application No  
PCT/IN 02/00220A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D207/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 02 43732 A (ISHAI ETI ; SAMBURSKY GUY (IL); TEVA PHARMA (IL); ARONHIME JUDITH ( ) 6 June 2002 (2002-06-06) page 19, line 10 - line 15 page 32; example 39 ---	1-11
Y	WO 97 03960 A (WARNER LAMBERT CO ; LIN MIN (US); SCHWEISS DIETER (US)) 6 February 1997 (1997-02-06) cited in the application claim 1 page 10 -page 11; example 2 ---	1-11
X	WO 01 42209 A (LEK TOVARNA FARMACEVTSKIH ; PFLAUM ZLATKO (SI)) 14 June 2001 (2001-06-14) cited in the application page 9; example 3 ---	1-11
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

11 March 2003

Date of mailing of the international search report

21/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kollmannsberger, M

## INTERNATIONAL SEARCH REPORT

Intern: Application No  
PCT/IN 02/00220

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 28999 A (EGYT GYOGYSZERVEGYESZETI GYAR ;SZENT KIRALLYI ZSUZSA (HU); VERECZK) 26 April 2001 (2001-04-26) cited in the application claims -----	1-11
A	WO 00 71116 A (THAPER RAJESH KUMAR ;KUMAR YATENDRA (IN); RANBAXY LAB LTD (IN); KU) 30 November 2000 (2000-11-30) cited in the application claims -----	1-11

# INTERNATIONAL SEARCH REPORT

nation on patent family members

Intern: Application No

PCT/IN 02/00220

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0243732	A	06-06-2002	AU 1792702 A WO 0243732 A1 US 2002183378 A1 AU 3289102 A WO 0243667 A2 US 2002099224 A1	11-06-2002 06-06-2002 05-12-2002 11-06-2002 06-06-2002 25-07-2002
WO 9703960	A	06-02-1997	AT 199542 T AU 700794 B2 AU 6497896 A BG 63631 B1 BG 102188 A BR 9609714 A CA 2220455 A1 CN 1190956 A ,B CZ 9800122 A3 DE 69611999 D1 DE 69611999 T2 DK 839132 T3 EA 625 B1 EE 9700369 A EP 0839132 A1 ES 2156997 T3 GR 3035859 T3 HR 960312 A1 HU 220343 B IL 122161 A JP 11510486 T NO 980209 A NZ 313008 A PL 324463 A1 PT 839132 T SI 839132 T1 SK 5898 A3 WO 9703960 A1 US 6274740 B1	15-03-2001 14-01-1999 18-02-1997 31-07-2002 31-08-1998 23-02-1999 06-02-1997 19-08-1998 16-12-1998 12-04-2001 26-07-2001 09-04-2001 29-12-1999 15-06-1998 06-05-1998 01-08-2001 31-08-2001 28-02-1998 28-12-2001 14-07-1999 14-09-1999 16-01-1998 28-01-2000 25-05-1998 29-06-2001 30-06-2001 05-08-1998 06-02-1997 14-08-2001
WO 0142209	A	14-06-2001	SI 20425 A AU 1543801 A EP 1237864 A1 WO 0142209 A1 SK 7832002 A3 US 2002183527 A1	30-06-2001 18-06-2001 11-09-2002 14-06-2001 06-11-2002 05-12-2002
WO 0128999	A	26-04-2001	HU 9903634 A2 AU 1166301 A CN 1379760 T CZ 20021256 A3 EP 1235800 A1 WO 0128999 A1 SK 5192002 A3	28-12-2001 30-04-2001 13-11-2002 14-08-2002 04-09-2002 26-04-2001 06-11-2002
WO 0071116	A	30-11-2000	AU 1996700 A BR 0010923 A CN 1351493 T EP 1185264 A1 WO 0071116 A1	12-12-2000 16-07-2002 29-05-2002 13-03-2002 30-11-2000